Insense forges ahead with novel oxygenating wound dressing, negotiates with several potential partners
This article was originally published in Clinica
An easy-to-wear dressing that incorporates a biochemical "motor" to produce wound-healing oxygen and iodine molecules could provide a new class of product for the advanced treatment of chronic conditions such as pressure sores and diabetic ulcers.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.